BioCentury | Feb 5, 2019
Financial News

Real-world analytics company Aetion tops off series B

...details. The company said it has raised $77 million since its launch in 2015. Allison Johnson Aetion Inc. Sanofi Sanofi Genzyme BioVentures UCB...
BioCentury | Jul 21, 2017
Financial News

NeuroVia raises $14M in series A

Rare disease company NeuroVia Inc. (San Francisco, Calif.) raised $14 million on July 20 in a series A round led by Novartis Venture Fund (NVF) and Sanofi-Genzyme BioVentures (SGBV). Also participating were BioMed Ventures and...
BioCentury | Jul 20, 2017
Financial News

NeuroVia raises $14M in series A

Rare disease company NeuroVia Inc. (San Francisco, Calif.) raised $14 million in a series A round led by Novartis Venture Fund (NVF) and Sanofi-Genzyme BioVentures (SGBV). Also participating were BioMed Ventures and Enso Ventures. Founder...
BioCentury | Mar 9, 2017
Finance

Pharmas learn their A, B, seeds

Having stepped in to fill the venture funding void after the financial crisis, corporate VCs are emerging as financing engines for new company formation. Driven largely by the flood of interest in immuno-oncology, pharmas are...
BioCentury | Nov 4, 2016
Strategy

The next (re)generation

Regenerative medicine is continuing to draw believers from the scientific and investment communities, who are putting stock in the technology’s potential to create transformational therapies. But while there’s plenty of enthusiasm for the scientific progress,...
BioCentury | Oct 24, 2016
Financial News

Science 37 completes venture financing

Science 37 Inc. , Culver City, Calif. Business: Supply/Service Date completed: 2016-10-18 Type: Venture financing Raised: $31 million Investors: Redmile Group; Lux Capital; dRx Capital; Sanofi-Genzyme BioVentures...
BioCentury | Oct 18, 2016
Financial News

Science 37 raises $31M in series B

...by Redmile Group. Existing investors Lux Capital and dRx Capital also participated, as well as Sanofi Genzyme BioVentures...
BioCentury | Apr 25, 2016
Emerging Company Profile

Yeast on the brain

Yumanity Therapeutics LLC is using an iterative loop of phenotypic screens to tackle diseases caused by misfolded proteins. The company, led by veteran biotech executive Tony Coles and backed by investors with long-term horizons, is...
BioCentury | Apr 4, 2016
Financial News

ImmuneXcite completes venture financing

ImmuneXcite Inc. , Watertown, Mass. Business: Cancer, Infectious, Antibodies Date completed: 2016-03-30 Type: Venture financing Raised: $8.6 million Investors: Cormorant Asset Management; Sanofi-Genzyme BioVentures; Partners Innovation Fund Note: The financing is a series A-1 round. WIR...
BioCentury | Feb 15, 2016
Finance

Breaking from tradition

Traditional VCs are missing from the new series A syndicate backing Yumanity Therapeutics LLC , and the biotech says that was its plan. The neurodegeneration company wanted investors with exceedingly long time horizons and the ability...
Items per page:
1 - 10 of 42
BioCentury | Feb 5, 2019
Financial News

Real-world analytics company Aetion tops off series B

...details. The company said it has raised $77 million since its launch in 2015. Allison Johnson Aetion Inc. Sanofi Sanofi Genzyme BioVentures UCB...
BioCentury | Jul 21, 2017
Financial News

NeuroVia raises $14M in series A

Rare disease company NeuroVia Inc. (San Francisco, Calif.) raised $14 million on July 20 in a series A round led by Novartis Venture Fund (NVF) and Sanofi-Genzyme BioVentures (SGBV). Also participating were BioMed Ventures and...
BioCentury | Jul 20, 2017
Financial News

NeuroVia raises $14M in series A

Rare disease company NeuroVia Inc. (San Francisco, Calif.) raised $14 million in a series A round led by Novartis Venture Fund (NVF) and Sanofi-Genzyme BioVentures (SGBV). Also participating were BioMed Ventures and Enso Ventures. Founder...
BioCentury | Mar 9, 2017
Finance

Pharmas learn their A, B, seeds

Having stepped in to fill the venture funding void after the financial crisis, corporate VCs are emerging as financing engines for new company formation. Driven largely by the flood of interest in immuno-oncology, pharmas are...
BioCentury | Nov 4, 2016
Strategy

The next (re)generation

Regenerative medicine is continuing to draw believers from the scientific and investment communities, who are putting stock in the technology’s potential to create transformational therapies. But while there’s plenty of enthusiasm for the scientific progress,...
BioCentury | Oct 24, 2016
Financial News

Science 37 completes venture financing

Science 37 Inc. , Culver City, Calif. Business: Supply/Service Date completed: 2016-10-18 Type: Venture financing Raised: $31 million Investors: Redmile Group; Lux Capital; dRx Capital; Sanofi-Genzyme BioVentures...
BioCentury | Oct 18, 2016
Financial News

Science 37 raises $31M in series B

...by Redmile Group. Existing investors Lux Capital and dRx Capital also participated, as well as Sanofi Genzyme BioVentures...
BioCentury | Apr 25, 2016
Emerging Company Profile

Yeast on the brain

Yumanity Therapeutics LLC is using an iterative loop of phenotypic screens to tackle diseases caused by misfolded proteins. The company, led by veteran biotech executive Tony Coles and backed by investors with long-term horizons, is...
BioCentury | Apr 4, 2016
Financial News

ImmuneXcite completes venture financing

ImmuneXcite Inc. , Watertown, Mass. Business: Cancer, Infectious, Antibodies Date completed: 2016-03-30 Type: Venture financing Raised: $8.6 million Investors: Cormorant Asset Management; Sanofi-Genzyme BioVentures; Partners Innovation Fund Note: The financing is a series A-1 round. WIR...
BioCentury | Feb 15, 2016
Finance

Breaking from tradition

Traditional VCs are missing from the new series A syndicate backing Yumanity Therapeutics LLC , and the biotech says that was its plan. The neurodegeneration company wanted investors with exceedingly long time horizons and the ability...
Items per page:
1 - 10 of 42